Collaborative Research Center 1066: Nanodimensional polymer therapeutics for tumor therapy
The focus in the collaborative research center (CRC) 1066 lies on the development of a nanocarrier based treatment against melanoma. The therapeutic principle being aimed at is the immunotherapy, since melanoma is an immunogenic tumor model. For this purpose nanocarriers are being developed to target different cell populations within a patient. While certain delivery systems are directed to the principal tumor sites, others should find their way to cells of the immune system – e.g. dendritic cells or T-cells – to stimulate an immune response. Different target cells also mean different cargo molecules for the delivery systems, so that a library of specifically designed delivery systems is needed from the synthetic side of view. Thus, an interdisciplinary team of researchers such as chemists, physicists, pharmacists and immunologists is needed to develop those kinds of systems.
Within the CRC the projects are divided into three main groups with a different focus: (A) Chemical projects involving the synthesis of a broad variety of tailor-functionalized polymeric nanocarriers, (B) Immunology-based projects which apply the synthesized nanocarriers for the generation of inflammation inside the tumor, immune response stimulation and neutralization of tumor tolerance and (Q) connecting projects directed at the precise characterization of all nanocarriers in biological environments from fluids like blood plasma to in vivo behavior.
The Landfester Group is active in all three project groups starting with the synthesis of novel carrier systems over the characterization of protein-nanocarrier interactions to the application of carrier systems in cell experiments.